Browse drugs

…umab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. 49.3% of patients were taking maintena…

…-year analyses from the real-world REALITI-A study demonstrated mepolizumab improvements in asthma control and lung function, a key outcome…

…s with severe asthma achieved clinical remission by 52 weeks of tezepelumab treatment.…

…ed quality of life (AQLQ), and maintenance oral corticosteroid (mOCS) use. Clinically meaningful improvement was defined as: ≥50% re…

…chieving clinical remission, demonstrating clinical benefits of Tezepelumab in managing severe asthma in routine care.…

…aphy (CBCT) and fluoroscopy are common adjuncts, used alongside ssRAB to enhance nodule localisation and improve diagnostic yield. Ho…

…re 373 s [291.3–619.8] for NR-BRJ and 370.5 s [276.0–527.5] for Plc-BRJ. A statistically significant increase in endothelial function, …

…/or intra-arterial chemotherapy. Patients received intravitreal topotecan (30 µg/0.1 mL) and/or intravitreal melphalan (20–30 µg/0.1 mL) …

…D exacerbations (primary endpoint) was significantly lower with astegolimab Q2W vs placebo (adjusted rate reduction 15%; P=0.0494), but not…

…d to receive either 1500 mg (n=12) or 500 mg (n=13) intravenous gremubamab—a monoclonal antibody targeting PcrV and Psl, PA virulence fact…

…clusion This is the first study to review TV-IBW targets during NIV initiation and possible correlations to clinical outcomes. Only…

…ith the addition of magnesium (6 mM) (n=6 IPF and n=13 NFC) and waixenicin A(500nM) (n=6). siRNA knockdown of TRPM7 inhibited TRPM7 function…